Osteopore Past Earnings Performance
Past criteria checks 0/6
Osteopore's earnings have been declining at an average annual rate of -26.4%, while the Medical Equipment industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 19.3% per year.
Key information
-26.4%
Earnings growth rate
134.2%
EPS growth rate
| Medical Equipment Industry Growth | 5.8% |
| Revenue growth rate | 19.3% |
| Return on equity | -1,126.2% |
| Net Margin | -219.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Osteopore makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -5 | 5 | 2 |
| 30 Sep 23 | 2 | -5 | 6 | 0 |
| 30 Jun 23 | 2 | -5 | 7 | 0 |
| 31 Mar 23 | 2 | -5 | 6 | 0 |
| 31 Dec 22 | 2 | -4 | 6 | 0 |
| 30 Sep 22 | 2 | -4 | 5 | 1 |
| 30 Jun 22 | 1 | -4 | 4 | 1 |
| 31 Mar 22 | 1 | -4 | 5 | 0 |
| 31 Dec 21 | 1 | -4 | 5 | 0 |
| 30 Sep 21 | 1 | -3 | 4 | 0 |
| 30 Jun 21 | 1 | -3 | 4 | 0 |
| 31 Mar 21 | 1 | -2 | 4 | 0 |
| 31 Dec 20 | 2 | -2 | 4 | 0 |
| 30 Sep 20 | 1 | -2 | 3 | 0 |
| 30 Jun 20 | 1 | -2 | 3 | 0 |
| 31 Mar 20 | 1 | -2 | 3 | 0 |
| 31 Dec 19 | 0 | -2 | 3 | 0 |
| 31 Dec 18 | 1 | -1 | 2 | 0 |
| 31 Dec 17 | 1 | 0 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
Quality Earnings: OSXDA is currently unprofitable.
Growing Profit Margin: OSXDA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OSXDA is unprofitable, and losses have increased over the past 5 years at a rate of 26.4% per year.
Accelerating Growth: Unable to compare OSXDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OSXDA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).
Return on Equity
High ROE: OSXDA has a negative Return on Equity (-1126.2%), as it is currently unprofitable.